Oncology News | pharmaphorum

News

J&J builds in CAR-T with $245m Cellular Biomedicine deal

Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil

News

Lynparza set for narrow prostate cancer use after FDA vote

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US.

News

EMA starts review of GSK’s Jemperli in endometrial cancer

GSK has moved a step closer to approval of its cancer immunotherapy Jemperli as a first-line treatment for endometrial cancer in the EU.

News

Nerve damage-tracking pen to be used in CAR-T patients

Nerve damage is a recognised side effect of some CAR-T therapies for cancer, and one that could be spotted early using a pen device developed by UK company Manus Neurodyna

News

J&J claims first approval for PARP combo Akeega

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm

News

BMS goes down the Tubulis route for cancer ADCs

Bristol-Myers Squibb has formed another alliance focusing on antibody-drug conjugates (ADCs) for solid tumours, paying German biotech Tubulis $22.75 million upfront to get

J&J builds in CAR-T with $245m Cellular Biomedicine deal

Lynparza set for narrow prostate cancer use after FDA vote

EMA starts review of GSK’s Jemperli in endometrial cancer

Nerve damage-tracking pen to be used in CAR-T patients

J&J claims first approval for PARP combo Akeega

BMS goes down the Tubulis route for cancer ADCs

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks